

36. American Society of Addiction Medicine (ASAM). The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use June 2015. <https://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf>. Accessed October 6, 2015.
37. Dowell D, Haegerich T, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016 *MMWR Recomm Rep*. 2016;65(1):1-49. <https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm>. Accessed November 7, 2017 doi:10.15585/mmwr.rr6501e1er.
38. Food and Drug Administration (FDA). Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS) 2013. <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM340914.pdf>. Accessed April 7, 2015.
39. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders* Vol 5th edition. Washington, DC: Author; 2013. https://www.amazon.com/Diagnostic-Statistical-Manual-Mental-Disorders/dp/0890425558/ref=sr_1_1?s=books&ie=UTF8&qid=1492003452&sr=1-1&keywords=dsm+5. Accessed August 10, 2013.
40. Sullivan J, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar) *Br J Addict*. 1989;84(11):1353-1357. <https://www.ncbi.nlm.nih.gov/pubmed/2597811>. Accessed March 16, 2017.